Anbio Biotechnology is breaking new ground in the European healthcare landscape with the introduction of the AF-100 C, a leading-edge compact fluorescent immunoassay analyzer. This innovative device, capable of conducting over 70 assays, is poised to significantly enhance patient care and diagnostic accuracy within the EU healthcare system.
In an ambitious move to extend its reach within the European Union, Anbio Biotechnology (Anbio), renowned for its leadership in vitro diagnostics, is delighted to unveil its comprehensive “Point of Care” product lineup in the EU. This expansion heralds a new era for Anbio, opening doors for collaboration with European distributors and healthcare providers and underscoring the firm’s dedication to providing the EU with top-tier diagnostic tools.
Anbio is acclaimed for its track record of innovation and a broad spectrum of diagnostic solutions that go beyond standard Covid test kits. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, Anbio’s Chief Executive Officer, announced.
Pioneering Analyzer with Comprehensive Testing Range
The spotlight of Anbio’s introduction to the EU market is on the AF-100 C analyzer, a sophisticated, handheld, rechargeable compact fluorescent Immunoassay (FIA) analyzer. With over 70 CE marked assays for a broad spectrum of analytes, the AF-100 C is set to revolutionize clinical diagnostics throughout Europe.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau commented. Its compact size belies its high throughput capability, making it perfectly suited for diverse clinical settings, thereby streamlining patient care.
Advancing Patient Care with Swift, Accurate Diagnostics
Anbio’s FIA tests promise swift turnaround times, from 3 to 15 minutes, signifying a substantial leap in diagnostic technologies. The innovative use of RFID chip technology in reagents ensures precision, and the ability to store these at room temperature for up to 24 months meets the immediate demands of the European healthcare industry.
As Anbio Biotechnology steps into the European arena, it invites healthcare professionals and distributors to discover its novel diagnostic solutions. With a commitment to enhancing patient care through cost-effective, accurate, and reliable diagnostics, Anbio is eager to collaborate with healthcare professionals throughout the EU.
